Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01421654 · ClinicalTrials.gov registry record · NA

Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy

A NA study, sponsored by ResMed.

Completed
Registry status
NA
Development phase
20
Enrollment target

NCT01421654 is a NA study that has completed, run by ResMed. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01421654, a NA study, has completed, sponsored by ResMed.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target

Study Summary

The purpose of the study is to evaluate if using the Acclimate feature at the beginning of Positive Airway Pressure (PAP) therapy results in patients using their PAP therapy at least as long as they would standard therapy. Additionally, the Acclimate feature will be evaluated with regard to patient comfort, ease of acceptance of PAP therapy, leak events, and respiratory events.

Interventions

  • DEVICE S9 Elite with Acclimate
  • DEVICE S9 Elite

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-09
Est. Completion 2011-12
Phase NA

Sponsor

ResMed

25 total trials

What the Registry Record Tells You About NCT01421654

The ClinicalTrials.gov registry entry for NCT01421654 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ResMed, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which S9 Elite with Acclimate is the first listed.

NCT01421654 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01421654 about?

NCT01421654 is a clinical study titled "Evaluation of Acclimate Feature for Positive Airway Pressure (PAP) Therapy". The purpose of the study is to evaluate if using the Acclimate feature at the beginning of Positive Airway Pressure (PAP) therapy results in patients using their PAP therapy at least as long as they would standard therapy. Additionally, the Acclimate feature will be evaluated with regard to patient ...

What is the current status of trial NCT01421654?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2011-09. Estimated completion is 2011-12.

What interventions are being tested in trial NCT01421654?

The interventions under investigation include: S9 Elite with Acclimate (DEVICE), S9 Elite (DEVICE).

Who is sponsoring clinical trial NCT01421654?

This trial is sponsored by ResMed, which has 25 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.